AU
UK
CA
US
IND
NZ
Last update at 2026-06-18T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Insider Buying Highlights 3 Undervalued Small Caps In Global Markets
Fri 13 Feb 26, 09:39 AM3 Undervalued Small Caps In Global With Insider Action
Thu 12 Feb 26, 09:39 AMFebruary 2026's Undervalued Small Caps With Insider Action In Global Markets
Wed 11 Feb 26, 09:39 AM3 Undiscovered European Gems With Strong Potential
Thu 01 May 25, 05:32 AM3 European Stocks Estimated To Be Up To 33.6% Below Intrinsic Value
Wed 30 Apr 25, 05:37 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 194.26M | 176.86M | 164.22M | 148.43M | 158.30M |
| Minority interest | - | - | - | - | - |
| Net income | 153.08M | 140.72M | 130.31M | 118.33M | 125.34M |
| Selling general administrative | 90.34M | 85.36M | 76.03M | 191.50M | 165.32M |
| Selling and marketing expenses | 129.88M | 136.59M | 136.62M | - | - |
| Gross profit | 519.88M | 487.07M | 463.04M | 438.32M | 392.30M |
| Reconciled depreciation | 40.05M | 41.01M | 39.76M | 40.10M | 33.44M |
| Ebit | 204.46M | 178.75M | 167.48M | 158.27M | 162.73M |
| Ebitda | 236.69M | 219.75M | 207.25M | 190.87M | 193.60M |
| Depreciation and amortization | 32.23M | 41.01M | 39.76M | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | 202.07M | 177.68M | 167.05M | 158.27M | 162.73M |
| Other operating expenses | 556.89M | 545.54M | 510.24M | - | - |
| Interest expense | 10.71M | 1.89M | 3.26M | 2.34M | 1.87M |
| Tax provision | 41.19M | 36.14M | 28.77M | 30.09M | 32.96M |
| Interest income | 2.90M | 7.34M | 0.78M | 0.20M | 0.06M |
| Net interest income | -7.80900M | -0.81900M | 5.08M | -2.14000M | -1.80600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 41.19M | 36.14M | 33.91M | 30.09M | 32.96M |
| Total revenue | 758.97M | 723.22M | 677.29M | 639.34M | 565.55M |
| Total operating expenses | 317.80M | 309.39M | 295.99M | 481.07M | 402.82M |
| Cost of revenue | 239.09M | 236.14M | 214.25M | 201.02M | 173.25M |
| Total other income expense net | -7.80900M | -0.81900M | -2.82900M | - | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 153.08M | 140.72M | 112.17M | 118.33M | 125.34M |
| Net income applicable to common shares | - | - | - | 118.33M | 125.34M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1094.89M | 1013.05M | 928.71M | 891.75M | 825.21M |
| Intangible assets | 408.20M | 359.51M | 99.58M | 275.09M | 244.07M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 2.12M | 20.11M | 0.87M | 0.90M |
| Total liab | 207.31M | 196.16M | 212.32M | 250.12M | 281.93M |
| Total stockholder equity | 887.58M | 815.73M | 716.39M | 641.63M | 543.28M |
| Deferred long term liab | - | - | - | 162.71M | 126.28M |
| Other current liab | 61.52M | 61.55M | 49.93M | 7.64M | 14.14M |
| Common stock | - | 3.58M | 3.58M | 3.58M | 3.58M |
| Capital stock | 3.58M | 3.58M | 3.58M | 3.58M | 3.58M |
| Retained earnings | 865.07M | 771.62M | 684.56M | 607.92M | 537.28M |
| Other liab | - | - | - | 56.66M | 51.59M |
| Good will | 120.68M | 128.14M | 123.78M | 124.14M | 114.08M |
| Other assets | - | -0.00100M | 0.00000M | 168.05M | 148.28M |
| Cash | 188.22M | 149.43M | 121.64M | 108.05M | 130.29M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 110.93M | 107.95M | 119.15M | 133.09M | 134.50M |
| Current deferred revenue | - | - | 0.00000M | - | - |
| Net debt | -162.56500M | -122.58100M | -56.94200M | - | - |
| Short term debt | 13.68M | 14.17M | 36.04M | - | - |
| Short long term debt | 13.68M | 14.17M | 36.04M | 42.13M | - |
| Short long term debt total | 25.65M | 26.85M | 64.70M | - | - |
| Other stockholder equity | 887.58M | 10.80M | 28.25M | 19.33M | -8.38300M |
| Property plant equipment | - | - | - | 110.03M | 80.33M |
| Total current assets | 441.09M | 401.65M | 365.59M | 377.14M | 364.72M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 405.11M | 311.39M |
| Short term investments | - | - | - | - | - |
| Net receivables | 141.07M | 125.28M | 97.80M | 121.89M | 115.50M |
| Long term debt | 11.97M | 12.68M | 28.66M | 60.36M | - |
| Inventory | 111.81M | 124.82M | 126.04M | 142.57M | 115.09M |
| Accounts payable | 35.73M | 32.22M | 32.53M | 47.86M | 44.86M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | 29.73M | 17.45M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.00639M | 2.65M | 214.26M | -0.00100M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 653.79M | 610.24M | 563.12M | 514.60M | 460.49M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.11M | -76.00600M | -87.69500M | -0.58100M | -0.03400M |
| Change to liabilities | - | - | - | 0.00000M | 0.00000M |
| Total cashflows from investing activities | -86.16300M | -76.00600M | -85.53200M | -70.01400M | -84.33900M |
| Net borrowings | -1.59800M | -28.96000M | -31.42100M | -42.70700M | -30.58700M |
| Total cash from financing activities | -74.59500M | -95.08900M | -97.03600M | -90.41000M | -48.47500M |
| Change to operating activities | - | - | - | 0.85M | 29.03M |
| Net income | 194.26M | 176.86M | 130.31M | 118.33M | 125.34M |
| Change in cash | 38.79M | 27.79M | 13.59M | -22.23300M | 28.02M |
| Begin period cash flow | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M |
| End period cash flow | 188.22M | 149.43M | 121.64M | 108.05M | 130.29M |
| Total cash from operating activities | 200.53M | 198.44M | 196.44M | 137.28M | 159.72M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 40.05M | 41.01M | 39.76M | 33.39M | 26.69M |
| Other cashflows from investing activities | 0.00028M | 1.74M | -54.70700M | 0.00100M | 0.00100M |
| Dividends paid | 59.63M | 53.67M | 53.67M | -47.70300M | -17.88900M |
| Change to inventory | 4.62M | -1.71400M | 12.62M | -26.32300M | -31.05800M |
| Change to account receivables | - | -15.79700M | 7.25M | -3.33000M | -9.84300M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -13.36800M | -12.46300M | -11.94900M | - | 0.00100M |
| Change to netincome | - | - | - | 7.66M | 12.81M |
| Capital expenditures | 86.27M | 77.75M | 86.48M | 23.48M | 13.72M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -3.18600M | -15.41200M | 10.39M | -28.80400M | -11.86900M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 9.45M | -4.01500M | 15.97M | -3.13600M | 6.45M |
| Free cash flow | 114.26M | 120.69M | 109.96M | 67.85M | 75.41M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLVSF CellaVision AB (publ) |
- -% | 13.49 | 22.64 | 20.79 | 4.65 | 3.98 | 4.78 | 15.41 |
| ABT Abbott Laboratories |
-0.58 0.66% | 87.83 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-3.11 1.01% | 304.69 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.07 0.09% | 79.27 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.96 2.12% | 44.33 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
MobilvAegen 12, Lund, Sweden, 223 62
| Name | Title | Year Born |
|---|---|---|
| Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D. | Founder & Director | 1965 |
| Mr. Simon Ostergaard | CEO & Pres | 1971 |
| Mr. Peter Wilson | VP of Global Marketing | 1967 |
| Mr. Yve van Thorenburg | Acting VP of Global Sales & Director of APAC of Global Sales | 1958 |
| Mr. Urban Strindlov | VP of Global Sales | 1964 |
| Nina Wallander | VP of HR | 1974 |
| Mr. Magnus Blixt | Exec. Officer | 1966 |
| Mr. Julien Veyssy | Managing Director of RAL Diagnostics | 1983 |
| Mr. Simon Ostergaard Ph.D. | CEO & President | 1971 |
| Mr. Magnus Blixt | Chief Financial Officer | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...